Application value of MRI diffuse weighted imaging combined with PET/CT in the diagnosis of stomach cancer at different stages

Sui,Yanbin; Zou,Zhenxing; Li,Fangfang; Hao,Cuijuan

doi:10.3892/ol.2019.10286

Application value of MRI diffuse weighted imaging combined with PET/CT in the diagnosis of stomach cancer at different stages

Authors:
- Yanbin Sui
- Zhenxing Zou
- Fangfang Li
- Cuijuan Hao
View Affiliations

Affiliations: Department of Medical Image, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Blood Purification, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: April 25, 2019 https://doi.org/10.3892/ol.2019.10286
Pages: 43-48

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Value of MRI diffusion‑weighted imaging (MRI DWI) combined with PET/CT in the diagnosis and staging of stomach cancer (SC) was investigated. A retrospective analysis was performed on 160 patients with SC diagnosed by pathological biopsy in The Affiliated Yantai Yuhuangding Hospital of Qingdao University from March 2015 to April 2018. The values of MRI DWI, PET/CT and combined diagnosis in the diagnosis and staging of SC were compared according to the criteria of diagnosis of postoperative pathological or clinical comprehensive evaluation. The sensitivity, specificity and diagnostic coincidence rate of MRI DWI in the diagnosis of SC at stage I-II were 61.05, 64.62 and 62.50%, respectively, which were significantly lower than those of PET/CT (P<0.05). Sensitivity, specificity and diagnostic coincidence rate of MRI DWI in the diagnosis of SC at stage III-IV were lower than those of PET/CT (P<0.05). Sensitivity and diagnostic coincidence rate of MRI DWI combined with PET/CT in the diagnosis of SC at stage I-II were significantly higher than those of MRI DWI or PET/CT alone (P<0.05). Specificity and diagnostic coincidence rate of MRI DWI combined with PET/CT in the diagnosis of SC at stage III-IV were significantly higher than those of MRI DWI or PET/CT alone (P<0.05). PET/CT is superior to MRI DWI in SC staging, whereas the diagnostic efficiency of combined scan is much higher than that of PET/CT or MRI DWI alone. In order to obtain more accurate preoperative staging and to avoid diagnostic exploratory laparotomy, the combination of MRI DWI and PET/CT techniques should be used in the comprehensive analysis of the disease to improve the accuracy of clinical diagnosis.

View Figures

View References

1	Balakrishnan M, George R, Sharma A and Graham DY: Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep. 19:362017. View Article : Google Scholar : PubMed/NCBI
2	Kodera Y: The current state of stomach cancer surgery in the world. Jpn J Clin Oncol. 46:1062–1071. 2016. View Article : Google Scholar
3	Yako-Suketomo H and Katanoda K: Comparison of time trends in stomach cancer mortality (1990–2006) in the world, from the WHO mortality database. Jpn J Clin Oncol. 39:622–623. 2009. View Article : Google Scholar : PubMed/NCBI
4	Yamamoto S: Stomach cancer incidence in the world. Jpn J Clin Oncol. 31:4712001.PubMed/NCBI
5	Lu J, Huang CM, Zheng CH, Li P, Xie JW, Wang JB and Lin JX: Analysis on the clinical and pathological features and prognosis of familial gastric cancer in South China population: A single-center study of 724 patients. J Oncol. 2012:6412182012. View Article : Google Scholar : PubMed/NCBI
6	Kudou M, Kosuga T, Kubota T, Okamoto K, Komatsu S, Shoda K, Konishi H, Shiozaki A, Fujiwara H, Arita T, et al: Value of preoperative PET-CT in the prediction of pathological stage of gastric cancer. Ann Surg Oncol. 25:1633–1639. 2018. View Article : Google Scholar : PubMed/NCBI
7	Joo I, Lee JM, Kim JH, Shin CI, Han JK and Choi BI: Prospective comparison of 3T MRI with diffusion-weighted imaging and MDCT for the preoperative TNM staging of gastric cancer. J Magn Reson Imaging. 41:814–821. 2015. View Article : Google Scholar : PubMed/NCBI
8	Low RN and Gurney J: Diffusion-weighted MRI (DWI) in the oncology patient: Value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging. 25:848–858. 2007. View Article : Google Scholar : PubMed/NCBI
9	Hansen AE, McEvoy F, Engelholm SA, Law I and Kristensen AT: FDG PET/CT imaging in canine cancer patients. Vet Radiol Ultrasound. 52:201–206. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cohade C, Osman M, Pannu HK and Wahl RL: Uptake in supraclavicular area fat (‘USA-Fat’): Description on ¹⁸F-FDG PET/CT. J Nucl Med. 44:170–176. 2003.PubMed/NCBI
11	Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP and Afshar-Oromieh A: Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 43:70–83. 2016. View Article : Google Scholar : PubMed/NCBI
12	Shin S, Pak K and Kim SJ, Kim H and Kim SJ: Pulmonary tumor embolism derived from stomach cancer observation with serial ¹⁸F-FDG PET/CT. Clin Nucl Med. 40:270–272. 2015. View Article : Google Scholar : PubMed/NCBI
13	Han K, Croke J, Foltz W, Metser U, Xie J, Shek T, Driscoll B, Ménard C, Vines D, Coolens C, et al: A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer. Radiother Oncol. 120:519–525. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wang TT, Qian XP and Liu BR: Survivin: Potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol. 13:2784–2790. 2007. View Article : Google Scholar : PubMed/NCBI
15	Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, et al: Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, ¹⁸F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 55:59–67. 2016. View Article : Google Scholar : PubMed/NCBI
16	Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PEZ and Hope TA: PET/MRI: Where might it replace PET/CT? J Magn Reson Imaging. 46:1247–1262. 2017. View Article : Google Scholar : PubMed/NCBI
17	Mhlanga JC, Chirindel A, Lodge MA, Wahl RL and Subramaniam RM: Quantitative PET/CT in clinical practice: Assessing the agreement of PET tumor indices using different clinical reading platforms. Nucl Med Commun. 39:154–160. 2018.PubMed/NCBI
18	Cazzato RL, Garnon J, Shaygi B, Koch G, Tsoumakidou G, Caudrelier J, Addeo P, Bachellier P, Namer IJ and Gangi A: PET/CT-guided interventions: Indications, advantages, disadvantages and the state of the art. Minim Invasive Ther Allied Technol. 27:27–32. 2018. View Article : Google Scholar : PubMed/NCBI
19	Stecco A, Buemi F, Cassarà A, Matheoud R, Sacchetti GM, Arnulfo A, Brambilla M and Carriero A: Comparison of retrospective PET and MRI-DWI (PET/MRI-DWI) image fusion with PET/CT and MRI-DWI in detection of cervical and endometrial cancer lymph node metastases. Radiol Med (Torino). 121:537–545. 2016. View Article : Google Scholar
20	Catalano OA, Daye D, Signore A, Iannace C, Vangel M, Luongo A, Catalano M, Filomena M, Mansi L, Soricelli A, et al: Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. Int J Oncol. 51:281–288. 2017. View Article : Google Scholar : PubMed/NCBI
21	Gaeta CM, Vercher-Conejero JL, Sher AC, Kohan A, Rubbert C and Avril N: Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Q J Nucl Med Mol Imaging. 57:352–366. 2013.PubMed/NCBI